ARCT vs. PLRX, OCUL, AUPH, LBPH, ALXO, SAGE, PRTC, NRIX, ELVN, and DNTH
Should you be buying Arcturus Therapeutics stock or one of its competitors? The main competitors of Arcturus Therapeutics include Pliant Therapeutics (PLRX), Ocular Therapeutix (OCUL), Aurinia Pharmaceuticals (AUPH), Longboard Pharmaceuticals (LBPH), ALX Oncology (ALXO), Sage Therapeutics (SAGE), PureTech Health (PRTC), Nurix Therapeutics (NRIX), Enliven Therapeutics (ELVN), and Dianthus Therapeutics (DNTH). These companies are all part of the "pharmaceutical preparations" industry.
Arcturus Therapeutics (NASDAQ:ARCT) and Pliant Therapeutics (NASDAQ:PLRX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, earnings, profitability, community ranking, risk and valuation.
94.5% of Arcturus Therapeutics shares are held by institutional investors. Comparatively, 97.3% of Pliant Therapeutics shares are held by institutional investors. 13.8% of Arcturus Therapeutics shares are held by insiders. Comparatively, 5.6% of Pliant Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Arcturus Therapeutics has higher revenue and earnings than Pliant Therapeutics. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks.
Arcturus Therapeutics has a beta of 2.6, indicating that its share price is 160% more volatile than the S&P 500. Comparatively, Pliant Therapeutics has a beta of 1.12, indicating that its share price is 12% more volatile than the S&P 500.
Pliant Therapeutics has a net margin of 0.00% compared to Arcturus Therapeutics' net margin of -15.65%. Arcturus Therapeutics' return on equity of -18.22% beat Pliant Therapeutics' return on equity.
Arcturus Therapeutics currently has a consensus target price of $61.33, suggesting a potential upside of 134.81%. Pliant Therapeutics has a consensus target price of $49.00, suggesting a potential upside of 326.46%. Given Pliant Therapeutics' higher probable upside, analysts plainly believe Pliant Therapeutics is more favorable than Arcturus Therapeutics.
Arcturus Therapeutics received 368 more outperform votes than Pliant Therapeutics when rated by MarketBeat users. However, 69.05% of users gave Pliant Therapeutics an outperform vote while only 65.34% of users gave Arcturus Therapeutics an outperform vote.
In the previous week, Arcturus Therapeutics had 1 more articles in the media than Pliant Therapeutics. MarketBeat recorded 3 mentions for Arcturus Therapeutics and 2 mentions for Pliant Therapeutics. Arcturus Therapeutics' average media sentiment score of 0.96 beat Pliant Therapeutics' score of -0.95 indicating that Arcturus Therapeutics is being referred to more favorably in the media.
Summary
Arcturus Therapeutics beats Pliant Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Arcturus Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ARCT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ARCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Arcturus Therapeutics Competitors List
Related Companies and Tools
